Literature DB >> 7630430

Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations.

C Schumacher1, H Becker, R Conrads, U Schotten, S Pott, M Kellinghaus, M Sigmund, F Schöndube, C Preusse, H D Schulte.   

Abstract

Only few data are available concerning the biochemical and functional state of the beta-adrenergic system in hypertrophied human myocardium. The present study was to investigate the myocardial beta-adrenergic signal transduction system in hypertrophic obstructive cardiomyopathy (HOCM). Thin myocardial strips were prepared from surgically excised, septal myocardium from 7 patients with HOCM and their force of contraction was measured in vitro. The positive inotropic effects of calcium and dihydro-ouabain, both acting independently of beta-adrenoceptors and cAMP, were similar in these preparations to those, previously published, seen with nonfailing myocardium. In contrast, the beta-adrenoceptor agonist isoprenaline and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) had reduced positive inotropic effects. Their EC50-values were about 10 fold higher than the respective EC50-values published for nonfailing myocardium. The positive inotropic potencies of isoprenaline and IBMX were reduced in HOCM by as much as they were in the additionally investigated myocardium from 6 patients with severe mitral regurgitation (MR, NYHA III). In order to clarify whether the functional alterations are related to changes in the beta-adrenoceptors, beta-adrenoceptor density and beta 1: beta 2-adrenoceptor subtype distribution were determined in the same myocardium using 125I-Iodocyanopindolol saturation binding. Myocardial beta-adrenoceptor density was reduced to 68% in HOCM and to 56% in MR compared to nonfailing myocardium controls (NF: 64.8 +/- 6.5 fmol/mg protein). In HOCM, this reduction was due to a selective down regulation of beta 1-adrenoceptors (24.9 +/- 3.7 fmol/mg protein vs NF: 46.4 +/- 6.8 fmol/mg protein, P < 0.05), whereas beta 2-adrenoceptor density was unchanged (19.0 +/- 1.9 fmol/mg protein vs NF: 18.4 +/- 3.3 fmol/mg protein, n.s.). In MR both beta-adrenoceptor subtypes were reduced (beta 1: 26.9 +/- 1.4 fmol/mg protein, beta 2: 9.6 +/- 1.7 fmol/mg protein; both P < 0.05 vs NF). Electrochemically determined plasma catecholamine levels were elevated in MR. However, plasma catecholamine levels were normal or slightly below normal in HOCM. In summary, myocardial beta-adrenoceptors are downregulated and their function is impaired in HOCM. This desensitization is not caused by a negative feedback regulation due to increased plasma catecholamines. The present results show that the desensitizations of the beta-adrenergic system associated with HOCM has characteristics that indicate a major deviation in its development from that of the beta-adrenergic desensitization previously described to occur in congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630430     DOI: 10.1007/bf00169081

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  50 in total

1.  Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium.

Authors:  M Böhm; D Beuckelmann; L Brown; G Feiler; B Lorenz; M Näbauer; B Kemkes; E Erdmann
Journal:  Eur Heart J       Date:  1988-08       Impact factor: 29.983

2.  Isovolumic relaxation period in hypertrophic cardiomyopathy: assessment by radionuclide angiography.

Authors:  S Betocchi; R O Bonow; S L Bacharach; D R Rosing; B J Maron; M V Green
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

3.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

Review 4.  Beta-adrenergic function in heart muscle disease and heart failure.

Authors:  M R Bristow; N E Kantrowitz; R Ginsburg; M B Fowler
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

5.  Beta-adrenoceptors and adenylate cyclase activity in hypertrophied and failing rabbit left ventricle.

Authors:  N Bouanani; A Corsin; N Gilson; B Crozatier
Journal:  J Mol Cell Cardiol       Date:  1991-05       Impact factor: 5.000

6.  Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation.

Authors:  M Böhm; B Pieske; P Schnabel; R Schwinger; B Kemkes; W P Klövekorn; E Erdmann
Journal:  J Cardiovasc Pharmacol       Date:  1989-10       Impact factor: 3.105

7.  Hypertrophic cardiomyopathy characterised by beta-adrenoceptor density, relative amount of beta-adrenoceptor subtypes and adenylate cyclase activity.

Authors:  S Golf; E Myhre; M Abdelnoor; D Andersen; V Hansson
Journal:  Cardiovasc Res       Date:  1985-11       Impact factor: 10.787

8.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

9.  Myocardial beta-adrenergic receptor expression and signal transduction after chronic volume-overload hypertrophy and circulatory congestion.

Authors:  H K Hammond; D A Roth; P A Insel; C E Ford; F C White; A S Maisel; M G Ziegler; C M Bloor
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

10.  Relationship between beta-adrenoceptors and calcium channels in human ventricular myocardium.

Authors:  D R Ferry; A J Kaumann
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

View more
  7 in total

1.  Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction.

Authors:  Ewa Soltysinska; Stefanie Thiele; Søren Peter Olesen; Oleg E Osadchii
Journal:  Pflugers Arch       Date:  2011-08-03       Impact factor: 3.657

Review 2.  Biophysical Derangements in Genetic Cardiomyopathies.

Authors:  Melissa L Lynn; Sarah J Lehman; Jil C Tardiff
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

Review 3.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

Review 4.  Beta-adrenergic receptors in failing human myocardium.

Authors:  O E Brodde
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 5.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

6.  Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.

Authors:  Chandra Prajapati; Marisa Ojala; Katriina Aalto-Setälä
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

Review 7.  Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier.

Authors:  Edgar E Nollet; B Daan Westenbrink; Rudolf A de Boer; Diederik W D Kuster; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-11-11       Impact factor: 6.106

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.